The U.S. Food and Drug Administration (FDA) has granted approval to GSK plc’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients suffering from inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This decision marks a significant advancement in the management of a challenging subset of COPD, offering a targeted biologic therapy to patients at high risk of exacerbations. The FDA’s approval is underpinned by ro...